India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar

India's Cipla said on Thursday its U.S. unit entered an ​exclusive partnership with China's Qilu Pharmaceutical ‌to license a biosimilar version of Merck's cancer drug Keytruda for the U.S. ​market.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。